Skip to main content

Table 1 Demographic and clinical characteristics

From: Rituximab, plasma exchange and immunoglobulins: an ineffective treatment for chronic active antibody-mediated rejection

 

Treatment

(N = 23)

Control

(N = 39)

P value

Dialysis vintage (months)

32.6 ± 24.2

41.3 ± 38.7

0.37

Donor Age

43.05 ± 15.69

50.89 ± 11.99

0.008

Donor type (Living donor)

9 (39.1%)

12 (30.7%)

0.5

First kidney transplant

13 (56.5%)

27 (69.2%)

0.31

HLA mistmatch (A, B, DR)

3.27 ± 1.1

3.8 ± 1.5

0.12

Desensitization (PE + RTX)

1 (4.34%)

1 (2.56%)

0.7

Induction (Yes)

16 (69.56%)

30 (76.92%)

0.52

 Thymoglobulin / ATG

10 (43.48%)

15 (38.46%)

0.7

 Basiliximab

3 (13.04%)

13 (33.3%)

0.8

 Other

3 (13.04%)

2 (5.12%)

0.3

IS at time of transplantation n (%)

 Tacrolimus + MMF/MPA + PDN

12 (52.2%)

24 (58.9%)

 

 Cyclosporine + MMF/MPA + PDN

3 (13.04%)

5 (12.82%)

 

 Cyclosporine + PDN

5 (21.74%)

3 (7.69%)

 

 mTORi + MMF/MPA + PDN

1 (4.35%)

5 (12.82%)

 

 Tacrolimus + mTORi + PDN

1 (4.35%)

1 (2.56%)

 

 Cyclosporine + mTORi + PDN

 

1 (2.56%)

 

 Cyclosporine + Azathioprine + PDN

1 (4.35%)

  

Previous treated rejections of this allograft

 Cellular rejection

6 (26.1%)

10 (25%)

0.97

 Humoral rejection

7 (30.4%)

6 (15.38%)

0.26

At the time of c-aABMR diagnosis

 Sex (Female/Male)

8/15

14/25

0.92

 Age (years)

43.59 ± 13.2

53.6 ± 16.1

0.013

 Charlson comorbidity index (CCI)

0.83 ± 1.1

0.97 ± 1.27

0.7

 Time KT to active c-aABMR (months)

92.2 ± 75

93.3 ± 55.1

0.67

 eGFR (mL/min) at c-aABMR diagnosis

30.9 ± 13.5

33.4 ± 11.6

0.45

 eGFR (mL/min) 6 months before cABMR

40 ± 11

42.9 ± 10.2

0.3

 Proteinuria (mg/g) at c-aABMR diagnosis

2286 ± 2248

1763 ± 1427

0.31

DSA (+)

6 /9

3 / 11

0.17

Anti-HLA Antibodies (+)

13 / 16

19 / 37

0.041

IS at time of c-aABMR diagnosis n (%)

 PDN + other IS

17 (73.9%)

22 (55%)

 

 Tacrolimus + MMF/MPA ± PDN

9 (39.1%)

17 (42.5%)

 

 mTORi + MMF/MPA ± PDN

2 (8.69%)

7 (17.5%)

 

 Cyclosporine + MMF/MPA ± PDN

4 (17.39%)

6 (15%)

 

 Tacrolimus + PDN

3 (13.04%)

4 (10%)

 

 MMF/MPA + PDN

1 (4.34%)

3 (7.5%)

 

 Cyclosporine ± PDN

2 (8.69%)

2 (5%)

 

 Tacrolimus + mTORi ± PDN

1 (4.34%)

1 (2.5%)

 

 Cyclosporine + mTORi

1 (4.34%)

  
  1. Results are shown as mean ± SD or absolute frequencies (%) for quantitative and qualitative variables respectively. GFR glomerular filtrate rate, KT kidney transplant, IS immunossupression, mTORi mammalian target of rapamycin inhibitor, MMF/MPA mycophenolate mofetil or mycophenolic acid, cABMR chronic antibody-mediated rejection; PDN, prednisone, RTX Rituximab